Form 4: Revolution Medicines CEO Mark Goldsmith Executes Stock Option and Sells Shares Under 10b5-1 Plan

Revolution Medicines CEO Mark Goldsmith exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan, while also transferring shares into a family trust.

Summary

• Mark A. Goldsmith, CEO of Revolution Medicines, executed a transaction involving the company's common stock on June 3, 2024.
• Goldsmith exercised a stock option to acquire 7,500 shares at a price of $4.09 per share.
• He then sold 7,500 shares in the open market at weighted average prices ranging from $39.0909 to $40.9333.
• These sales were executed under a pre-arranged 10b5-1 trading plan adopted on December 1, 2023.
• Goldsmith also transferred 138,057 shares previously held directly into a family trust.
• Following these transactions, Goldsmith directly owns 322,322 shares of common stock and indirectly owns 526,452 shares through various trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the CEO is selling shares, it's under a pre-arranged plan, mitigating negative implications. The transfer of shares to a family trust is a common estate planning activity.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can reassure investors that the sales were not based on insider information.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• While the 10b5-1 plan mitigates some concerns, significant insider selling could still create negative market sentiment.

Future Outlook

The document does not contain specific forward-looking statements, but it indicates ongoing transactions under the 10b5-1 trading plan.

Industry Context

Insider transactions are common in the pharmaceutical industry, and the use of 10b5-1 plans is a standard practice to avoid accusations of insider trading. Investors often monitor these transactions for insights into management's view of the company's prospects.

Comparison to Industry Standards

• Comparing Goldsmith's transactions to those of executives at similar-stage biotech companies like Relay Therapeutics or Black Diamond Therapeutics, the scale of the sales appears within a normal range for executives managing their personal portfolios.
• The use of a 10b5-1 plan is consistent with industry best practices, as seen with executives at companies like Amgen and Gilead Sciences.

Stakeholder Impact

• Shareholders may react to the CEO's stock sales, but the existence of a 10b5-1 plan should reassure them that the sales are not based on inside information.
• Employees may be indirectly affected by any changes in investor sentiment resulting from these transactions.

Key Dates